Apraclonidine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Apraclonidine
Apraclonidine: Known uses and market status in Canada
Summary
All of the TxGNN model’s candidates for Apraclonidine that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 0 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 00888354 | IOPIDINE | Valid | |
| 02076306 | IOPIDINE | Valid |
Safety Considerations
- Drug Interactions: 60 interactions were recorded. Most of the ones listed are of moderate severity, and one is major:
- Major: methylene blue
- Moderate (examples): opioids and related agents (morphine, opium, loperamide, diphenoxylate, difenoxin), cannabinoids (dronabinol, nabilone), ethanol, metoclopramide, promethazine, scopolamine, sibutramine, papaverine, and vasodilators or related agents (amyl nitrite, diazoxide, epoprostenol, iloprost, selexipag)
- Model-derived contraindication signals (these come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence; they are not from product label text and need verification against the official label): hypertension and hypertensive disorders; blood disorders (thrombocytopenia, thrombocytopenic purpura, neutropenia, agranulocytosis, aplastic anemia, Diamond-Blackfan anemia, blood coagulation disease); hyperlipidemia and familial hyperlipidemia; cholestasis and its familial forms; active peptic ulcer disease; intracerebral hemorrhage; leukemia; and scurvy or ascorbic acid deficiency.
- Paediatric use: the risk of CNS depression and apnoea with alpha-2 agonists is a significant concern for congenital or infantile glaucoma.
Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.